--- title: "Invivyd 公司(IVVD)讨论了 REVOLUTION 临床项目的进展以及麻疹单克隆抗体候选药物的推进情况" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/282283900.md" description: "Invivyd, Inc. (IVVD) 发布了一份幻灯片,讨论其 REVOLUTION 临床项目的进展。公司还强调了其麻疹单克隆抗体候选药物的进展。这些信息以幻灯片的形式呈现给投资者" datetime: "2026-04-10T03:40:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282283900.md) - [en](https://longbridge.com/en/news/282283900.md) - [zh-HK](https://longbridge.com/zh-HK/news/282283900.md) --- # Invivyd 公司(IVVD)讨论了 REVOLUTION 临床项目的进展以及麻疹单克隆抗体候选药物的推进情况 Invivyd, Inc. (IVVD) has released a slide deck discussing the progress of its REVOLUTION Clinical Program. The company also highlighted the advancement of its measles monoclonal antibody candidate. This information is presented in a slideshow format for investors. ### 相关股票 - [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [VHT.US](https://longbridge.com/zh-CN/quote/VHT.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [IXJ.US](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md) - [IVVD.US](https://longbridge.com/zh-CN/quote/IVVD.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) ## 相关资讯与研究 - [Scholar Rock 将出席杰富瑞全球医疗保健大会,聚焦 SMA 新药 apitegromab 关键审批](https://longbridge.com/zh-CN/news/287069556.md) - [百时美施贵宝向 3 万名员工全面开放 Anthropic 公司 Claude](https://longbridge.com/zh-CN/news/287085684.md) - [强生重症肌无力治疗新药获国家药监局批准上市](https://longbridge.com/zh-CN/news/287196062.md) - [礼来押注非病毒基因药物,斥资 2.02 亿美元收购 Engage Bio](https://longbridge.com/zh-CN/news/287086583.md) - [Invivyd|8-K:2026 财年 Q1 营收 13.74 百万美元不及预期](https://longbridge.com/zh-CN/news/286405997.md)